1-N-Boc-3-碘甲基哌啶 | 253177-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-N-Boc-3-碘甲基哌啶
• 中文别名: 3-碘甲基哌啶-1-甲酸叔丁酯；1-Boc-3-碘甲基哌啶；1-Boc-3-(碘甲基)哌啶
• 英文名称: 3-iodomethylpiperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 3-(iodomethyl)piperidine-1-carboxylate
• CAS: 253177-03-6
• 化学式: C₁₁H₂₀INO₂
• 分子量: 325.19
• InChiKey: GWYLEGFCHNTQTF-UHFFFAOYSA-N

物化性质

• 沸点：
  336.6±15.0 °C(Predicted)
• 密度：
  1.447

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C，需避光、干燥且密封保存。

反应信息

• 作为反应物：
  描述：

  1-N-Boc-3-碘甲基哌啶 在 四丁基氟化铵 、 碳酸氢钠 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 生成 3-((2S,3R)-2-Benzyloxycarbonyl-4-oxo-azetidin-3-ylmethyl)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase

  摘要：

  Azetidinones such as BMS-363131 (2) and BMS-363130 (3), which contain a guanidine group in the C-3 side chain were previously shown to be very potent inhibitors of human tryptase with high selectivity versus other serine proteases, including trypsin. In this letter, we describe the discovery of a number of potent azetidinone tryptase inhibitors in which the guanidine moiety at the ring C-3 position is replaced with primary or secondary amine or aminopyridine functionality. In particular, BMS-354326 (4) is a highly potent tryptase inhibitor (IC50 1.8 nM), which has excellent selectivity against trypsin and most other related serine proteases. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.011
• 作为产物：
  描述：

  3-哌啶甲酸乙酯 在 咪唑 、 lithium aluminium tetrahydride 、 碘 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 1-N-Boc-3-碘甲基哌啶
  参考文献：
  名称：

  Synthesis of potent and highly selective inhibitors of human tryptase

  摘要：

  The serine protease tryptase has been implicated in allergic and inflammatory diseases and associated with asthma. The synthesis and SAR of a series of N1-activated-4-carboxy azetidinones are described, resulting in identification of BMS-363131 (2) as a potent inhibitor of human tryptase (IC50 < 1.7 nM) with high selectivity (>3000-fold) for tryptase versus related serine proteases including trypsin. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00689-3

文献信息

• Beta lactam compounds and their use as inhibitors of tryptase
  申请人：Bristol-Myers Squibb Co.

  公开号：US06335324B1

  公开（公告）日：2002-01-01

  Compounds of the formulas: are disclosed. These compounds inhibit tryptase as well as other enzyme systems or are selective tryptase inhibitors and are useful as antiinflammatory agents particularly in the treatment of chronic asthma.

  这些化合物的结构式已被披露。这些化合物抑制色胺酸蛋白酶以及其他酶系统，或者是选择性色胺酸蛋白酶抑制剂，并且在特别是治疗慢性哮喘方面作为抗炎药物是有用的。
• [EN] BICYCLIC OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA BICYCLIQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018109198A1

  公开（公告）日：2018-06-21

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上核性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化或额颞叶痴呆症。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243528A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性麻痹; 以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩性侧索硬化或额颞叶痴呆。
• [EN] [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS<br/>[FR] DÉRIVÉS DE [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYLE SUBSTITUÉS PAR DE LA PIPÉRIDINE, DE LA MORPHOLINE OU DE LA PIPÉRAZINE UTILISÉS EN TANT QU'INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018154133A1

  公开（公告）日：2018-08-30

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包括这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及利用这些化合物和组合物预防和治疗抑制OGA有益的疾病的用途，如tau病变病，特别是阿尔茨海默病或进行性上颌核瘤；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或颞叶前叶痴呆症。
• Heterocyclic analgesic compounds and methods of use thereof
  申请人：——

  公开号：US20020016337A1

  公开（公告）日：2002-02-07

  One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

  本发明的一个方面涉及新颖的杂环化合物。本发明的第二个方面涉及将这些新颖的杂环化合物作为各种细胞受体的配体，包括阿片受体、其他G蛋白偶联受体和离子通道。本发明的另一个方面涉及将这些新颖的杂环化合物用作镇痛剂。